OSRH completed a transformational business combination that dramatically expanded the company's asset base by 7,335% while generating massive operating losses and negative equity.
The company has undergone a complete transformation from Bellevue Life Sciences Acquisition Corp. through a business combination that closed after their fiscal year end, resulting in a fundamentally different entity. While assets surged from $2.3M to $171.2M, the company is now generating substantial losses with operating income declining from -$3.5M to -$18.3M and is technically insolvent with -$8.3M in stockholders' equity.
The financial statements reflect a dramatic corporate transformation with total assets exploding 7,335% to $171.2M and liabilities increasing 403% to $44.2M, suggesting a major acquisition or business combination. However, profitability deteriorated severely with the company swinging from $404K net income to -$2.4M loss, operating losses quintupling to -$18.3M, and stockholders' equity turning deeply negative at -$8.3M. The overall picture suggests a high-growth expansion strategy that has significantly increased the company's scale but at the cost of profitability and financial stability, creating both substantial opportunity and elevated risk for investors.
Asset base grew 7335.3% — expansion through organic growth, acquisitions, or capital deployment.
Cash position surged 2470.9% — strong cash generation or capital raise providing significant financial cushion.
Net income declined 697.1% — review whether driven by operations, interest costs, or non-recurring items.
Current assets grew 518.5% — improving short-term liquidity or inventory/receivables build.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Liabilities grew 402.9% — significant increase in debt or obligations, assess impact on financial flexibility.
Current liabilities surged 155.5% — significant near-term obligations; verify ability to meet short-term debt.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Operating cash flow fell 97.8% — earnings quality concerns; investigate working capital changes and non-cash items.
R&D investment increased 97.6% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →